Synergy Pharmaceuticals Inc. (SGYP) At $2.23 Forms Bottom; Amedisys, Inc. (AMED) Had 7 Bulls

Among 15 analysts covering Amedisys Inc. (NASDAQ:AMED), 7 have Buy rating, 0 Sell and 8 Hold. Therefore 47% are positive. Amedisys Inc. had 39 analyst reports since September 1, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Hold” on Monday, July 10. Benchmark initiated Amedisys, Inc. (NASDAQ:AMED) on Friday, January 27 with “Hold” rating. Robert W. Baird maintained the stock with “Neutral” rating in Wednesday, January 13 report. The stock of Amedisys, Inc. (NASDAQ:AMED) earned “Buy” rating by Mizuho on Monday, November 7. The stock of Amedisys, Inc. (NASDAQ:AMED) earned “Buy” rating by William Blair on Tuesday, January 23. The firm has “Hold” rating given on Sunday, October 22 by RBC Capital Markets. The firm has “Equal-Weight” rating by Stephens given on Friday, June 17. The firm earned “Buy” rating on Thursday, November 2 by Mizuho. Raymond James upgraded the shares of AMED in report on Monday, January 11 to “Mkt Perform” rating. The stock of Amedisys, Inc. (NASDAQ:AMED) has “Buy” rating given on Wednesday, February 28 by Jefferies. See Amedisys, Inc. (NASDAQ:AMED) latest ratings:

01/03/2018 Broker: Robert W. Baird Rating: Hold New Target: $66.0 Maintain
28/02/2018 Broker: Jefferies Rating: Buy New Target: $70.0 Maintain
23/01/2018 Broker: William Blair Rating: Buy Maintain
10/11/2017 Broker: Robert W. Baird Rating: Neutral Old Target: $50 New Target: $60 Maintain
09/11/2017 Broker: Craig Hallum Rating: Buy New Target: $68.0 Maintain
09/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $62.0 Maintain
09/11/2017 Broker: Benchmark Old Rating: Buy New Rating: Hold Downgrade
08/11/2017 Broker: Mizuho Rating: Buy New Target: $65.0 Maintain
05/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $50.0 Maintain
02/11/2017 Broker: Mizuho Old Rating: Neutral New Rating: Buy Upgrade

Synergy Pharmaceuticals Inc. (SGYP) formed multiple bottom with $2.16 target or 3.00% below today’s $2.23 share price. Synergy Pharmaceuticals Inc. (SGYP) has $550.05M valuation. The stock increased 5.69% or $0.12 during the last trading session, reaching $2.23. About 5.86 million shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since March 8, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

The stock increased 1.68% or $0.99 during the last trading session, reaching $59.98. About 184,281 shares traded. Amedisys, Inc. (NASDAQ:AMED) has risen 15.02% since March 8, 2017 and is uptrending. It has underperformed by 1.68% the S&P500.

Investors sentiment increased to 1.77 in Q3 2017. Its up 0.06, from 1.71 in 2017Q2. It improved, as 26 investors sold Amedisys, Inc. shares while 29 reduced holdings. 30 funds opened positions while 64 raised stakes. 31.75 million shares or 5.19% more from 30.18 million shares in 2017Q2 were reported. Parametric Assoc Ltd accumulated 83,106 shares. Vanguard Gp, a Pennsylvania-based fund reported 2.62M shares. Guggenheim Limited Liability Corporation has 0% invested in Amedisys, Inc. (NASDAQ:AMED). Citigroup Incorporated owns 20,152 shares. State Of Tennessee Treasury Department reported 0.01% in Amedisys, Inc. (NASDAQ:AMED). Jpmorgan Chase & Communications invested 0% in Amedisys, Inc. (NASDAQ:AMED). Alliancebernstein Limited Partnership owns 105,558 shares or 0% of their US portfolio. Sg Americas Securities Ltd Limited Liability Company has 4,219 shares. Royal Retail Bank Of Canada accumulated 25,881 shares. Pillar Pacific Cap Management Ltd Liability Corporation has invested 0.05% of its portfolio in Amedisys, Inc. (NASDAQ:AMED). First Midwest Savings Bank Division has 19,923 shares for 0.14% of their portfolio. Morgan Stanley has invested 0% in Amedisys, Inc. (NASDAQ:AMED). Eaton Vance reported 0.03% stake. Texas Permanent School Fund invested in 0.01% or 20,765 shares. Victory Capital Management reported 548,819 shares.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The company has market cap of $2.04 billion. It operates through three divisions: Home Health, Hospice, and Personal Care. It has a 68.16 P/E ratio. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.